A recently published study by Fact.MR suggests that the global gene therapy market is projected to grow at a compound annual growth rate (CAGR) of 18.5% from 2022 to 2032, reaching a valuation of US$10.1 billion. 

By 2022, the market is expected to reach a value of US$1.85 billion. The increasing pursuit of breakthroughs in medical treatments has driven the demand for gene therapy across various grades.

Between 2015 and 2021, the market experienced a value CAGR of 18.7%, reaching a value of US$1.55 billion. The demand for gene therapy further surged during the COVID-19 pandemic, as healthcare providers raced to develop potent vaccines to combat the outbreak. Additionally, key healthcare providers utilized advanced gene therapeutics to conduct clinical trials for essential drug candidates. 

Oncology research is anticipated to present lucrative growth opportunities for gene therapy providers. In 2020, according to Globocan, approximately 19 million new cancer cases and 9,958,133 cancer-related deaths were reported worldwide. Various gene therapy strategies are currently being employed in cancer treatment, including anti-angiogenic gene therapy, pro-drug activating suicide gene therapy, immune modulation through gene therapy, oncolytic virotherapy, gene defect correction/compensation, antisense therapy, genetic manipulation of apoptotic and tumor invasion pathways, and RNAi strategies. 

Key Insights from the Market Study:

  • Yescarta-based gene therapy is expected to generate 44.5% of the market revenue by 2032.
  • Luxturna-based gene therapy is projected to capture a 36% revenue share by 2032.
  • Europe is poised to emerge as one of the most promising gene therapy markets, with a CAGR exceeding 19%.
  • The APAC market reached a value of US$351 million in 2021 and is forecasted to grow at an 18.3% CAGR.
  • North America is predicted to be the most lucrative gene therapy landscape, contributing 56% of the revenue.
  • The global gene therapy market is expected to grow over fivefold from 2022 to 2032. 


"Given the increasing incidence of chronic and lifestyle-induced diseases, healthcare providers are exploring advanced gene therapy options to develop effective diagnostics and therapeutics, driving R&D efforts at various levels," commented a Fact.MR analyst. 

Competitive Landscape: 

The global gene therapy market is highly competitive, with only a few major players dominating the industry. Companies such as Amgen Inc., Bluebird Bio, Gilead Sciences, Inc., Novartis AG, Orchard Therapeutics, Sibiono GeneTech Co. Ltd., Spark Therapeutics (Roche AG), and UniQure N.V. hold significant market shares in the gene therapy market. 

In October 2021, the National Institutes of Health, the United States Food and Drug Administration, ten pharmaceutical companies, and five non-profit organizations announced a collaborative effort to accelerate the development of gene therapies for the 30 million Americans suffering from rare diseases. Such initiatives are expected to bolster the demand for gene therapy.